Trial Profile
A Randomized, Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Cabotegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ViiV Healthcare
- 12 Sep 2021 Results (n=986) of population pharmacokinetics of the rilpivirine long-acting from seven clinical studies (TMC278-C158 (NCT01031589), TMC278LAHTX1001(NCT02547870), TMC278LAHTX1002 (NCT03127189) and LAI115428(NCT01593046) LATTE-2 (NCT02120352) (NCT02951052) and(NCT02938520) published in the Journal of Antimicrobial Chemotherapy
- 27 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2013 Results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.